HER2 Heterogeneity in Gastric Cancer: A Comparative Study, Using Two Commercial Antibodies

Satala, Catalin Bogdan; Jung, Ioan; Staden, Raluca Ioana Stefan-van; Kovács, Zsolt; Molnar, Călin; Bara, Tivadar; Fülöp, Zsolt; Gurzu, Simona

doi:10.1155/2020/8860174

Cited by 10 publications

(7 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As can be seen from the statistics above, roughly 35.5 percent of patients in the Abd El Salam et al [1] research had lymphovascular invasion, whereas approximately 18.4 percent had perineural invasion. Satala et al [18] reported that roughly 18.2% of their patients had distant metastases.…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

The Expression of E-cadherin & HER2 in Gastric Carcinoma

El-Mihy

Hasby

Noseir

et al. 2022

JAMMR

View full text Add to dashboard Cite

Background and Aim: Cell adhesion molecules (often referred to as cadherins) are glycoproteins found in the cell membrane. They regulate biological processes such as cell migration, differentiation, proliferation, and death (apoptosis). Her-2 is a proto-oncogene that belongs to the EGFR protein family. In cellular processes such as cell growth, regulates cellular activities such as proliferation, differentiation, and survival. This study aimed to determine the expression of E-cadherin and HER2 in the available histologic subtypes and evaluate if there is a correlation between E-cadherin and HER2 immunohistochemical expression in gastric carcinoma. Subjects & Methods: A total of 50 cases of stomach cancer were included in this study, all of which were obtained retrospectively between January 2017 and January 2020 from the Pathology Department, Tanta University, Egypt and Tanta Cancer Center archives. The samples were obtained from gastroplastectomy specimens then stained using the immunostaining approach described as follows: Deparaffinization and rehydration followed by using 3-hydroxy-4-napthylbenzaldehyde (3-OH-4-NHB) as a starting material then a smorgasbord of antigens then exposing to primary antibodies then exposing to a secondary biotinylated antibody, after that identifying of enzymes using streptavidin-labeled enzymes then preparing a color working reagent and last complexity in the development of color. Results: E-cadherin was statistically significantly high in tumors exhibiting aggressive clinicopathologic characteristics specifically in males, all histopathologic variants (except for poorly differentiated tubular adenocarcinoma and signet ring carcinoma), N stages, M stages, higher in absent vascular invasion cases but lower in present cases and the same with perineural invasion cases. Tumor site had no significant impact on the levels of E-cadherin. HER2 showed statistically insignificant correlations with all factors. E-cadherin and HER2 expression showed statistically insignificant relationship. Conclusion: Elevated E-cadherin expression is associated with tumors that exhibit aggressive clinicopathologic characteristics. HER2 was expressed positively in low-grade variants, but no correlation was established with clinical characteristics. E-cadherin and HER2 expression have no discernible relationship.

show abstract

Section: Discussionmentioning

confidence: 98%

“…This was consistent with Satala et al (2020). 's [18] finding that 11.8 percent of cases without distant metastasis were HER2-positive, and 11.7 percent of those with distant metastasis were HER2-positive (3). Motoshima et al [35] detected this in 44% of cases with distant metastases.…”

Section: Discussionmentioning

confidence: 99%

The Expression of E-cadherin & HER2 in Gastric Carcinoma

El-Mihy

Hasby

Noseir

et al. 2022

JAMMR

View full text Add to dashboard Cite

show abstract

“…Thirdly, the intratumoral heterogeneity is commonly seen in gastric cancer [ 26 ]. Although testing in at least 3–4 slides was recommended to minimize the error caused by intratumorally heterogeneity [ 27 ], more exhaustive and accurate determination of HER-2 expression remains an open problem.…”

Section: Discussionmentioning

confidence: 99%

Prognostic and clinical significance of HER-2 low expression in early-stage gastric cancer

Yang

You

et al. 2022

BMC Cancer

View full text Add to dashboard Cite

Introduction Gastric cancer is the most fifth common tumor worldwide. Human epidermal growth factor receptor 2 (HER2) overexpression is associated with poor prognosis and clinical characteristics in gastric cancer. Nevertheless, the biology of HER2-low expression has not reported in gastric cancer. Materials and methods A total of 157 patients with early-stage gastric cancer were retrospectively analyzed. The associations between HER-2 low expression and clinical characteristics were analyzed by Chi-square test. And the prognostic value of HER-2 low expression and clinical characteristics in disease-free survival (DFS) and overall survival (OS) were analyzed by univariate and multivariate Cox regression analysis. Results Of 157 patients with early-stage gastric cancer, 31.8% had HER2-low tumors and 50.3% had HER2-negative tumors. HER2-low expression was associated with age, histological differentiation, tumor location and Ki-67 index. However, HER2-low expression was not associated with DFS or OS in early-stage gastric cancer. Conclusion HER2-low expression might result in distinct biology, but it was not an independent prognostic factor of DFS or OS in early-stage gastric cancer.

show abstract

“…GC is a highly heterogenous disease and caution is advised when assessing HER2 status, particularly when determined with IHC [ 40 ]. Several protocols were placed to promote reproducibility of HER2 testing in GC in light of the technical, tumor-related, sample-related and interpretation-related issues faced in this context.…”

Section: Discussionmentioning

confidence: 99%

Prevalence of Her2-neu status and its clinicopathological association in newly diagnosed gastric cancer patients

et al. 2022

View full text Add to dashboard Cite

Background This study aimed to report the prevalence of HER2-neu in newly diagnosed early or metastatic gastric cancer (GC) patients, to determine the percentage of patients achieving various IHC scores correlating with the ISH results and to establish a database for GC patients in Lebanon. Methods This was a national, multicenter, descriptive and cross-sectional study in patients with histologically confirmed early or metastatic GC newly diagnosed. All eligible patients underwent the IHC and ISH tests in a central laboratory. Demographics, medical history and histopathology data were collected. Results One hundred fifty-seven patients were included (mean age at diagnosis: 63 ± 14.1 years) during a 3.5 year period. The prevalence of HER2-neu over expression was 21% (95% CI: 15.3–27.4) using ICH and ISH. Agreement between IHC and ISH results was significantly substantial (kappa = 0.681; p-value < 0.001). Over expressed HER2-neu status was significantly associated with high ECOG performance status only. Conclusions The prevalence of HER2-neu over expression in newly diagnosed early or metastatic GC patients seemed to be high in Lebanon. The database generated allows to monitor trends in the epidemiology and management of GC.

show abstract

HER2 Heterogeneity in Gastric Cancer: A Comparative Study, Using Two Commercial Antibodies

Cited by 10 publications

References 33 publications

The Expression of E-cadherin & HER2 in Gastric Carcinoma

The Expression of E-cadherin & HER2 in Gastric Carcinoma

Prognostic and clinical significance of HER-2 low expression in early-stage gastric cancer

Prevalence of Her2-neu status and its clinicopathological association in newly diagnosed gastric cancer patients

Contact Info

Product

Resources

About